Open an account Help & support Register Account summary Log out
Skip Header
Home Stock market news

Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

AstraZeneca launches strategic research collaboration with China's CSPC Pharmaceuticals

Fri 13 Jun 2025 09:51

(Sharecast News) - Drugmaker AstraZeneca revealed on Friday that it has entered a strategic research collaboration with Chinese firm CSPC Pharmaceuticals Group. AstraZeneca stated that both it and CSPC had agreed to discover and develop pre-clinical candidates for multiple targets with the potential to treat diseases across chronic indications, including a pre-clinical small-molecule oral therapy for immunological diseases.

Research will be carried out by CSPC in Shijiazhuang City and will utilise the firm's AI-driven, dual-engine, efficient drug discovery platform.

CSPC will receive an upfront payment of $110.0m, and will also be eligible to receive up to $1.62bn in potential development milestone payments and up to $3.6bn in sales milestone payments, plus potential single-digit royalties based on annual net sales of the products.

Meanwhile, AstraZeneca will have the right to exercise options for exclusive licenses to develop and commercialise worldwide candidates identified under the agreement.

AstraZeneca's Sharon Barr said: "This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases which impact over two billion people globally. Forming strong collaborations allows us to leverage our complementary scientific expertise to support the rapid discovery of high-quality novel therapeutic molecules to deliver the next-generation medicines."

As of 1025 BST, AstraZeneca shares were down 0.30% at 10,996.36p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Wed 19 Aug 2026 14:30
Oakley Capital Investments acquires enterprise AI data platform Graphwise
(Sharecast News) - London-listed Oakley Capital Investments announced on Wednesday that one of its funds has acquired knowledge graph and semantic data technology firm Graphwise.
Wed 19 Aug 2026 13:48
Thursday preview: Walmart, Hays, JD Sports results due
(Sharecast News) - On Thursday, UK corporate releases will include full-year results from recruiter Hays and a trading statement from sportswear retailer JD Sports.
Wed 19 Aug 2026 11:46
DiscoverIE expands manufacturing capacity in India
(Sharecast News) - DiscoverIE Group announced a "major expansion" of its manufacturing capacity in India on Wednesday, opening a new facility in Bangalore to meet growing domestic and international demand.
Wed 19 Aug 2026 11:17
Pinewood Technologies to be taken over by Ridgeview in £545m deal
(Sharecast News) - Software company Pinewood Technologies said on Wednesday that it has agreed to be taken over by technology investor Ridgeview Partners in a £545m deal.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Awards

Award 1
Award 2
Award 3

Policies and important information

Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Statutory and Regulatory disclosures | Whistleblowing programme

Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.

This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.

© FIL Limited 2026